Latest Biotech News

Gilead Sciences is moving aggressively into autoimmune immunology by announcing the planned acquisition of Ouro Medicines for $2.17 billion (including $1.675 billion upfront) and adding Ouro’s...

Merck is slated to acquire Terns Pharmaceuticals in a $6.7 billion cash deal as it targets a differentiated oncology asset built around TERN-701 for chronic myeloid leukemia. The reported...

Pfizer’s trispecific antibody tilrekimig (targets IL-13, IL-4, and TSLP) produced statistically significant improvements in atopic dermatitis in a Phase II program, meeting its primary endpoint....

Maze Therapeutics reported positive mid-Stage data in its Phase 2 study of MZE829, a genetic kidney disease therapy that targets a mechanism intended to compete in the same target space as...

Karyopharm is preparing for regulatory discussions with the U.S. Food and Drug Administration after topline Phase III results in myelofibrosis. The company said the Xpovio (selinexor) plus...

Roche won CE marking for its Cobas Eplex respiratory pathogen panel 3 (RP3), bringing a fast, syndromic molecular test to markets accepting the designation. The panel differentiates up to 25 viral...

RyboDyn raised $10 million in seed funding to pursue oncology target discovery by exploring the “dark proteome”—previously uncharacterized peptides and non-canonical RNA-derived outputs in patient...

Q&A coverage around endometriosis testing and women’s health diagnostics highlighted a growing push toward earlier diagnosis using noninvasive menstrual-blood multiomics. Multiple women-led...

Liquid biopsy company Virchow Medical completed a $4 million seed financing led by Cerberus Ventures to expand access to liquid specimen collection and its biorepository approach. The company...

Verana Health and Guardant Health partnered to provide biopharma researchers with connected precision medicine data assets spanning regulatory-grade electronic health record cohorts and...

Gilead Sciences agreed to acquire Ouro Medicines in a $2.17 billion deal to add OM336 (gamgertamig), a BCMAxCD3 T-cell engager, to its inflammation portfolio. The transaction includes $1.675...

Merck struck a multi-year collaboration with Quotient Therapeutics to use its somatic genomics platform to identify drug targets in inflammatory bowel disease. Merck will pay $20 million upfront,...

Karyopharm reported mixed top-line results from its Phase 3 Sentry trial of 60-mg Xpovio (selinexor) plus ruxolitinib in front-line myelofibrosis. The study met the first co-primary endpoint,...

Sanofi agreed to license and obtain exclusive worldwide rights to Kali Therapeutics’ trispecific T-cell engager KT501 in a deal that could generate more than $1.23 billion for the private biotech....

BrightGene reported early Phase 1 data for BGM0504, its oral GLP-1/GIP dual agonist, showing dose-dependent weight loss after short dosing periods in both China and the U.S. In the China study (75...

RA Capital Management formed a new blank-check entity, “Research Alliance III,” targeting a merger or acquisition with a biotechnology or healthcare company in China. The venture firm plans to...

RyboDyn closed a $10 million seed financing to accelerate its program for identifying oncology drug targets in the “dark proteome.” The startup’s platform, RyboCypher, combines deep sequencing of...

A cluster of women-led healthcare firms is developing noninvasive, multiomics tests for earlier endometriosis diagnosis using menstrual fluid. The companies are building assays that focus on...

The FDA issued a warning letter to ImmunityBio over “false and misleading” claims made in a TV advertisement and a podcast about Anktiva, the company’s bladder cancer treatment marketed as...

The UK government announced an inquiry by the House of Lords Science and Technology Committee to examine how artificial intelligence can optimize clinical trials and bridge gaps between early...